STAAR SURGICAL CO (STAA) stock intrinsic value fair value estimate & owner earnings analysis

STAAR Surgical makes the EVO implantable collamer lens (ICL), a lens placed inside the eye to correct nearsightedness without laser surgery. Essentially all sales come from ICLs, and the company keeps about 74% to 78% of each sales dollar as gross profit. The difficulty is everything below that line. Operating costs rose from $145 million in 2021 (on $230 million of sales) to $228 million in 2025 before one-time items, and sales then fell from $322 million in 2023 to $239 million in 2025 because the two distributors that sell the lens in China, which had bought ahead of demand, stopped ordering. China sales were $184.6 million in 2023, $162.3 million in 2024 and $77.8 million in 2025 (the 2025 figure includes $27.5 million from a December 2024 shipment sold on extended terms and recognized when paid). Outside China, sales kept growing: $137.8 million, $151.6 million and $161.7 million. How we measure earnings. We count operating cash flow, remove swings in receivables, inventory and payables, then charge the cost of stock given to employees ($30.6 million in 2025) and the capital spending needed to stay in business. We left the $13.4 million (2024) and $15.8 million (2025) spent implementing new cloud-based business software inside earnings as a real cost rather than treating it as working capital. On this basis the business earned the following per share (before the interest adjustment described next): 2016 -$0.27, 2017 $0.07, 2018 $0.22, 2019 $0.16, 2020 $0.08, 2021 $0.43, 2022 $0.58, 2023 $0.33, 2024 -$0.80, 2025 -$1.41. Because the company's roughly $180 million of cash is valued separately, we take the interest it earns ($7.0 million in 2023, $5.9 million in 2024, $4.6 million in 2025) out of the earnings stream so it is not counted twice. Over the full ten years this business has, on average, lost money for owners; the median of 2018 to 2025 (a window that covers the build-out, the China boom and the reset) is about $0.17 per share, or roughly $9 million a year, and that is the level we use. We cross-checked it against a bottom-up build (about $310 million of sales at a 74% gross margin against a cost base of roughly $222 million a year, after setting aside the merger-termination and restructuring charges the company reported) and it holds up. Our earnings measure is slightly generous in recent years because it keeps non-cash lease and provision charges added back while removing the working-capital lines that offset them, which is why we cross-checked it. Direction of earnings. Owner earnings in the last full year (2025) worsened from -$0.80 to -$1.41 per share. For the base case we do not assume growth from the $0.17 level. The return to positive earnings is supported by the first half of 2026: operating income of $18.1 million (after about $9 million of merger-termination and restructuring charges, as reported by the company) against an $87.4 million operating loss in the first half of 2025, on $187.1 million of sales, with total operating costs at $120.5 million for the half. Two straight quarters of roughly $93.5 million of sales (Q2 operating income $10.1 million) support a profitable base; we do not lift the level further because China, the source of the rebound, more than doubled year over year to $52.3 million in the second quarter after a year of destocking, and the company's own annual report says weak Chinese consumer demand is expected to continue to weigh in 2026. Cash also lagged: first-half operating cash flow was -$2.0 million despite $13.3 million of net income, because receivables rose from $50.1 million to $98.5 million (the Chinese distributors account for about two-thirds of them, per the company's report). Even so, cash and investments fell only $6.0 million in the half, from $187.5 million to $181.5 million. Debt and cash. STAAR has no borrowings. It holds $181.5 million of cash and investments, which is $3.52 per share on 51.5 million diluted shares. We treat $30 million as needed to run the business, leaving $2.94 per share of excess cash in the base and bull cases; in the bear case all of it is counted because the cash burn is modeled explicitly. Bear case: $2.18 per share. The China reset of 2023 to 2025 (down 58%) happens again and sticks: China sales settle near $60 million a year (the 2.5-year average of about $136 million cut by that same percentage), low-cost Asian ICL competitors named in the filings take share, and non-China sales stay at $162 million. Sales of about $222 million at a 73% gross margin leave costs of $215 million, $190 million and $170 million in the next three years before management cuts to $160 million (the company ran at $145 million in 2021 on similar sales). Owner earnings per share would be -$1.01, -$0.52, -$0.14 and then about $0.02. The operation is worth -$1.34 per share, the company owes nothing, and the $3.52 of cash per share (about $86 million of which is consumed by the losses) leaves $2.18. We left out any release of working capital as receivables shrink, and any rescue financing, because neither is evidenced. Base case: $5.01 per share. Owner earnings of $0.17 per share (about $9 million), held level for ten years with no growth credited, then fading 5% a year because nothing we can name replaces the lens franchise's earning power once competition from lower-priced Asian lenses matures. The operating business is worth $2.07 per share; there is no debt; plus $2.94 of excess cash gives $5.01. We left out growth from procedure volumes, the EVO+ launch in China (March 2026 quarter) and non-China growth (the Americas and Asia-Pacific excluding China grew in the second quarter; EMEA was flat) because they depend on a market expanding or share gains that the company has not yet demonstrated through a full cycle. Bull case: $13.18 per share. The first-half 2026 pace holds: China near $200 million a year (above the 2023 level, helped by the EVO+ launch) and non-China sales of $175 million. At $375 million of sales, a 74.3% margin and today's $222 million cost base, operating income is about $57 million and owner earnings about $0.84 per share, held level for ten years and fading 5% thereafter. The operation is worth $10.23 per share, there is no debt, and the excess cash adds $2.94. What changed since our last estimate. The previous figures (bear $4.43, base $11.57, bull $24.18) were prepared on a different basis and are not comparable. On the business itself the main change is a leadership team in transition: a new chief executive and chief financial officer were appointed in August 2026 after the failed sale to Alcon (the merger was voted down on January 6, 2026, no termination fee was paid, and the largest holder, Broadwood, with about 31% of the shares, installed three directors under a January 2026 cooperation agreement). Margin-of-safety price: $2.50. We are only moderately sure of the earnings level. Sales depend on two Chinese distributors holding about two-thirds of receivables, China sales fell 58% in two years, and each $10 million of China sales moves owner earnings by roughly $0.10 per share, so the same company has produced both -$1.41 and, on the first-half pace, a run rate near $0.85. The worst plausible outcome we can build leaves about $2 in cash with a smaller business. Outcomes no case models include a collection problem on the $98.5 million of receivables (a distributor already asked for extended terms once, in December 2024, and paid in full), a tariff or regulatory shock in China before all China-bound lenses are made in Switzerland (targeted for the end of 2026), and an enterprise-software rollout that management says required extensive manual work. There is no debt to turn any of these into a crisis, and the cash is hard. If we are wrong on China the shares are worth about $2 to $3.50; if we are wrong the other way they are worth up to about $13. The price assumes about a three-year holding period, and the business pays no dividend during it, only interest on cash. At $2.50 the price is below the cash on the balance sheet ($3.52 per share), with no value assigned to the lens business; the worst case we can build implies roughly a 13% loss, and the base case implies over 25% a year if reached within three years. The margin-of-safety price would be higher only if the cash and receivables conversion shows that the first-half sales are real demand rather than restocking, which is why it is not higher.